Fragile X syndrome, an inherited cause of autism and intellectual disability, can have consequences even for carriers of the disorder who don’t have full-blown symptoms. Researchers at Washington University School of Medicine in St. Louis have identified a potential target for treatment for fragile X carriers.
New research from the School of Medicine’s Albert Kim, MD, PhD (left), and Hiroko Yano, PhD, helps explain how mutations in the gene that causes Huntington’s disease kill brain cells. The findings could open new opportunities for treating the fatal disorder.
Leading scientists have selected the first drugs to be evaluated in a worldwide clinical trial to determine whether they can prevent Alzheimer’s disease. The pioneering trial, expected to start by early 2013, initially will test three promising drugs, each designed to target Alzheimer’s in different ways.